MAP BioPharma
Patient Access 2021

Patient Access Insights

Putting things into perspective: What does the EU HTA mean for companies?

A panel discussion addressed the impact of the EU HTA on companies as of 2024.
Request this webinar
MAP BioPharma Patient Access Insights

Putting things into perspective: What does the EU HTA mean for companies?

Originally Broadcast: Tuesday 7th September 2021

Learning objectives:

In this webinar you will:

  •  Understand the opportunities and challenges of the new EU HTA system

  •  Learn about how companies can better understand and prepare for the new submission process, which will likely start in 2024 with ATMPs and cancer medicines

  •  Recognise the legal background to obtain a positive HTA outcome for all EU countries

  •  Discover how this might impact existing supranational organisations and processes, such as BeNeLuxA, FINOSE, VALETTA and EUnetHTA – for example, it could become a vehicle for implementation of the EU HTA in groups of countries

  •  Benefit from the EU “one-stop-shop” HTA approach

Who should attend:

This webinar should be attended by those interested in cell and gene therapies and orphan medicines and how they can remove obstacles to patient access. This is aimed at BioPharma and MedTech companies as well as patient organisations and patient groups.

• Heads of Market Access

• Managing Directors

• Country Managers

• Chief Executives

• Medical Directors

• Commercial Directors

• Policy Officers/Executives

• Marketing Directors

• Policy Advisors


Please note, this webinar is only available to BioPharma and MedTech companies. This webinar will be recorded and distributed after the session. 

To get the most value from this session, please send us your questions in advance. Email your questions to enquiries@mapbiopharma.com.

Speakers:

Christian Hill, CEO, MAP BioPharma

Christian is a seasoned Market Access professional with over 20 years of experience in the International Biotech and Pharmaceutical industry. He has been involved in over 50 HTAs across Europe and has built up a strong network of key influencers including EU and national agencies. Prior to co-founding MAP in 2012, he led market access teams and submissions at InterMune, Gilead, Pfizer and Genzyme on a very broad range of products and disease areas from chronic disease to ultra-orphan indications.

Christian is a member of the Board of EUCOPE (European Confederation of Pharmaceutical Entrepreneurs); he is also a member of the Steering Group of EMIG (Ethical Medicines Industry Group) in the UK and Ireland.

Dr Alexander Natz, Secretary General, EUCOPE

Alexander Natz is the Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (www.eucope.org) in Brussels and works as a lawyer in the healthcare boutique law firm NOVACOS in Düsseldorf (www.novacos-law.com). He advises innovative pharmaceutical and biotech companies, including start-ups, in regulatory and pricing & reimbursement matters from the EU law and German law perspective.

From 2008 to 2013, he was Head of the Brussels Office of Bundesverband der Pharmazeutischen Industrie eV (BPI). Before, he has been a lawyer at Sträter Law Firm in Germany with a special focus on managed entry agreements and licensing of pharmaceuticals. Dr. Natz has also worked in the field of competition law with the European Commission and in the pharmaceutical industry.

Steve Beard, Chief Consulting Officer, MAP BioPharma

Speakers:

Christian Hill


Christian Hill, CEO, MAP BioPharma

Christian is a seasoned Market Access professional with over 20 years of experience in the International Biotech and Pharmaceutical industry. He has been involved in over 50 HTAs across Europe and has built up a strong network of key influencers including EU and national agencies. Prior to co-founding MAP in 2012, he led market access teams and submissions at InterMune, Gilead, Pfizer and Genzyme on a very broad range of products and disease areas from chronic disease to ultra-orphan indications.

Christian is a member of the Board of EUCOPE (European Confederation of Pharmaceutical Entrepreneurs); he is also a member of the Steering Group of EMIG (Ethical Medicines Industry Group) in the UK and Ireland.

Dr Alexander Natz


Dr Alexander Natz, Secretary General, EUCOPE

Alexander Natz is the Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (www.eucope.org) in Brussels and works as a lawyer in the healthcare boutique law firm NOVACOS in Düsseldorf (www.novacos-law.com). He advises innovative pharmaceutical and biotech companies, including start-ups, in regulatory and pricing & reimbursement matters from the EU law and German law perspective.

From 2008 to 2013, he was Head of the Brussels Office of Bundesverband der Pharmazeutischen Industrie eV (BPI). Before, he has been a lawyer at Sträter Law Firm in Germany with a special focus on managed entry agreements and licensing of pharmaceuticals. Dr. Natz has also worked in the field of competition law with the European Commission and in the pharmaceutical industry.

Steve Beard


Steve Beard, Chief Consulting Officer, MAP BioPharma

linkedin.com/in/steve-beard-0b831519/   

CareersTerms and ConditionsComplaints ProcedurePrivacy PolicyCookie Policy

Copyright © 2021.
MAP BioPharma Limited.
All rights reserved.

MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
United Kingdom

 +44 (0) 1480 832360

 enquiries@mapbiopharma.com

MAP BioPharma Limited is a registered company in England and Wales.
Company Registration Number 08209281

VAT Group Registration Number:
GB 292 8576 52